Current approaches to pharmacological treatment of adult patients with bronchiectasis
https://doi.org/10.18093/0869-0189-2019-29-1-71-86
Abstract
Bronchiectasis is a chronic airway disease. Currently, no evidence-based recommendations on pharmacological treatment of bronchiectasis have been developed in the world. Published data is not sufficient to clear assessment of efficacy of pharmacological and non-pharmacological treatment for those patients. The main goals of treatment of bronchiectasis are to prevent exacerbations, to control symptoms, to improve quality of life, and to slow down progression of the disease. This article is a review of published data on efficacy and a role of selected pharmacological therapies of bronchiectasis and bronchial clearance techniques in adult patients.
About the Authors
S. Yu. Chikina
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University)
Russian Federation
Russian Federation
Svetlana Yu. Chikina - Candidate of Medicine; Assistant Lecturer.
Trubetskaya ul. 8, build 2, Moscow, 119991; tel.: (916) 116-04-03.
S. N. Avdeev
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Sergey N. Avdeev - Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Deputy Director for Science, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Chief Pulmonologist, Healthcare Ministry of Russia.
Trubetskaya ul. 8, build 2, Moscow, 119991; Orekhovyy bul'var 28, Moscow, 115682; tel.: (495) 708-35-76.
References
1. Bilton D., Jones A.L. Bronchiectasis: epidemiology and causes. In: Floto R.A., Haworth C.S., eds. Bronchiectasis. Eur. Respir. Monograph. 2011; 52: 239–247. DOI: 10.1183/1025448x.erm5210.
2. Vendrell M., de Gracia J., Olveira C. et al. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery]. Arch. Bronconeumol. 2008; 44 (11): 629–640 (in Spanish).
3. Chalmers J.D., Aliberti S., Blasi F. Management of bronchiectasis in adults. Eur. Respir. J. 2015; 45: 1446–1462. DOI: 10.1183/09031936.00119114.
4. Loebinger M.R., Wells A.U., Hansell D.M. et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34: (4): 843–849. DOI: 10.1183/09031936.00003709.
5. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016; 71 (12): 1110–1118. DOI: 10.1136/thoraxjnl-2016-208481.
6. Finch S., McDonnell M.J., Abo-Leyah H. et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (11): 1602–1611. DOI: 10.1513/AnnalsATS.201506-333OC.
7. Snijders D., Fernandez Dominguez B., Calgaro S. et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence? Int. J. Immunopathol. Pharmacol. 2015; 28 (2): 150–159. DOI: 10.1177/0394632015584724.
8. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir. Med. 2016; 4 (12): 969–979. DOI: 10.1016/S2213-2600(16)30320-4.
9. Du Q., Jin J., Liu X., Sun Y. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: A systematic review and meta-analysis. PLoS One. 2016; 11 (3): e0150532. DOI: 10.1371/journal.pone.0150532.
10. Navaratnam V., Muirhead C.R., Hubbard R.B., De Soyza A. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. QJM. 2016; 109 (8): 523–526. DOI: 10.1093/qjmed/hcv206.
11. Navaratnam V., Millett E.R., Hurst J.R. et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax. 2017; 72 (2): 161–166. DOI: 10.1136/thoraxjnl-2015-208188.
12. Chalmers J.D., Goeminne P., Aliberti S. et al. The bronchiectasis severity index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 2014; 189 (5): 576–585. DOI: 10.1164/rccm.201309-1575OC.
13. Chalmers J.D., Smith M.P., McHugh B.J. et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186 (7): 657–665. DOI: 10.1164/rccm.201203-0487OC.
14. Sheehan R.E., Wells A.U., Copley S.J. et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur. Respir. J. 2002; 20 (3): 581–587. DOI: 10.1183/09031936.02.00284602.
15. Aliberti S., Lonni S., Dore S. et al. Clinical phenotypes in adult patients with bronchiectasis. Eur. Respir. J. 2016; 47 (4): 1113–1122. DOI: 10.1183/13993003.01899-2015.
16. Kapur N., Masters I.B., Chang A.B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: What influences lung function stability? Chest. 2010; 138: 158–164.
17. Chalmers J.D., Aliberti S., Polverino E. et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. 2016; 2: 00081-2015.
18. Lee A.L., Burge A.T., Holland A.E. Airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2015; (11): CD008351. DOI: 10.1002/14651858.CD008351.pub3.
19. Muñoz G., de Gracia J., Buxó M. et al. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur. Respir. J. 2018; 51 (1): pii: 1701926. DOI: 10.1183/13993003.01926-2017.
20. Wong C., Sullivan C., Jayaram L. ELTGOL airway clearance in bronchiectasis: laying the bricks of evidence. Eur. Respir. J. 2018; 51 (1): pii: 1702232. DOI: 10.1183/13993003.02232-2017.
21. Lee A.L., Burge A.T., Holland A.E. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2017; (9): CD011699. DOI: 10.1002/14651858.CD011699.pub2.
22. Polverino E., Goeminne P.C., McDonnell M.J. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017; 50: 1700629. DOI: 10.1183/13993003.00629-2017.
23. Tarrant B. J., Le Maitre C., Romero L. et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017; 22: 1084–1092. DOI: 10.1111/resp.13047.
24. Hart A., Sugumar K., Milan S.J. et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD002996. DOI: 10.1002/14651858.CD002996.pub3.
25. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105 (12): 1831–1835. DOI: 10.1016/j.rmed.2011.07.019.
26. Nicolson C.H., Stirling R.G., Borg B.M. et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106: 661–667.
27. Kellett F., Redfern J., Niven R.M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 2005; 99 (1): 27–31.
28. Herrero-Cortina B., Alcaraz V., Vilaró J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (5). DOI: 10.1089/jamp.2017.1443.
29. Máiz L., Girón R.M., Prats E. et al. Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients. Ther. Adv. Respir. Dis. 2018; 12: 1753466618787385. DOI: 10.1177/1753466618787385.
30. Bilton D., Tino G., Barker A.F. et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69: 1073–1079.
31. Yang C., Chilvers M., Montgomery M., Nolan S.J. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. 2016; (4): CD001127. DOI: 10.1002/14651858.CD001127.pub3.
32. O’Donnell A.E., Barker A.F., Ilowite J.S., Fick R.B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998; 113 (5): 1329–1334.
33. Wills P.J., Wodehouse T., Corkery K. et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. J. Respir. Crit. Care Med. 1996; 154 (2): 413–417. DOI: 10.1164/ajrccm.154.2.8756815.
34. Hassan J.A., Saadiah S., Roslan H., Zainudin B.M. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology. 1999; 4 (4): 423–426.
35. Jeong H.J., Lee H., Carriere K.C. et al. Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 2757–2764.
36. Tsang K.W., Ho P.L., Lam W.K. et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am. J. Respir. Crit. Care Med. 1998; 158 (3): 723–727.
37. Martínez-García M.A., Perpiñá-Tordera M., Román-Sánchez P., Soler-Cataluña J.J. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir. Med. 2006; 100 (9): 1623–1632.
38. Kapur N., Petsky H.L., Bell S. et al. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst. Rev. 2018; (5): CD000996. DOI: 10.1002/14651858.CD000996.pub3.
39. Wei P., Yang J.W., Lu H.W. et al. Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study. Medicine (Baltimore). 2016; 95 (42): e5116.
40. Martínez-García M.Á.,Soler-Cataluña J.J., Catalán-Serra P. et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012; 141 (2): 461–468. DOI: 10.1378/chest.11-0180.
41. Lee J.K., Lee J., Park S.S. et al. Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Int. J. Tuberc. Lung Dis. 2014; 18 (3): 363–370. DOI: 10.5588/ijtld.13.0255.
42. Jang E.J., Lee C.H., Yoon H.I. et al. Association between inhaler use and risk of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Respirology. 2015; 20 (8): 1213–1221. DOI: 10.1111/resp.12618.
43. Pasteur M.C., Bilton D., Hill A.T. et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 (Suppl. 1): i1–58. DOI: 10.1136/thx.2010.136119.
44. McShane P.J., Naureckas E.T., Tino G., Strek M.E. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 647–656. DOI: 10.1164/rccm.201303-0411CI.
45. Dhand R. The rationale and evidence for use of inhaled antibiotics to control pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (3): 121–138. DOI: 10.1089/jamp.2017.1415.
46. Brodt A.M., Stovold E., Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur. Respir. J. 2014; 44 (2): 382–393. DOI: 10.1183/09031936.00018414.
47. Paredes Aller S., Quittner A.L., Salathe M.A., Schmid A. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis–experiences from recent clinical trials. Expert. Rev. Respir. Med. 2018; 3: 1–14. DOI: 10.1080/17476348.2018.1503540.
48. Avdeev S.N., Karchevskaya N.A. [The first experience of treatment with nebulized tobramycin in patients with exacerbation of bronchiectasis]. Pul’monologiya. 2011; (4): 133–138 (in Russian).
49. Ovcharenko S.I., Kapustina V.A. [Efficacy and safety of nebulized tiamphenicoli glycynate acetylcysteinate in therapy of chronic respiratory diseases]. Prakticheskaya meditsina. 2013; 5 (74): 102–105 (in Russian).
50. Haworth C.S., Foweraker J.E., Wilkinson P. et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014; 189 (8): 975–982. DOI: 10.1164/rccm.201312-2208OC.
51. Murray M.P., Govan J.R., Doherty C.J. et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011; 183 (4): 491–499. DOI: 10.1164/rccm.201005-0756OC.
52. De Soyza A., Aksamit T., Bandel T.J. et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702052. DOI: 10.1183/13993003.02052-2017.
53. Aksamit T., De Soyza A., Bandel T.J. et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702053. DOI: 10.1183/13993003.02053-2017.
54. Chotirmall S.H., Chalmers J.D. RESPIRE: breathing new life into bronchiectasis. Eur. Respir. J. 2018; 51 (1): pii: 1702444. DOI: 10.1183/13993003.02444-2017.
55. Bilton D., Serisier D.J., De Soyza A.T. et al. Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2011; 38: 1925.
56. Serisier D.J., Bilton D., De Soyza A. et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013; 68 (9): 812–817. DOI: 10.1136/thoraxjnl-2013-203207.
57. Haworth C., Wanner A., Froehlich J. et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: Results from two parallel phase III trials (ORBIT-3 and -4). Am. J. Respir. Crit. Care Med. 2017; 195: A7604.
58. Barker A.F., O'Donnell A.E., Flume P. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014; 2 (9): 738–749. DOI: 10.1016/S2213-2600(14)70165-1.
59. Drobnic M.E., Suñé P., Montoro J.B. et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa. Ann. Pharmacother. 2005; 39: 39–44.
60. Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–485.
61. Zimmermann P., Ziesenitz V.C., Curtis N., Ritz N. The immunomodulatory effects of macrolides – a systematic review of the underlying mechanisms. Front. Immunol. 2018; 9: 302. DOI: 10.3389/fimmu.2018.00302.
62. Kelly C., Chalmers J.D., Crossingham I. et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst. Rev. 2018; (3): CD012406. DOI: 10.1002/14651858.CD012406.pub2.
63. Wong C., Jayaram L., Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 660–667. DOI: 10.1016/S0140-6736(12)60953-2.
64. Altenburg J., de Graaff C.S., Stienstra Y. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013; 309 (12): 1251–1259. DOI: 10.1001/jama.2013.1937.
65. Serisier D.J., Martin M.L., McGuckin M.A. et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309 (12): 1260–1267. DOI: 10.1001/jama.2013.2290.
66. Li W., Qin Z., Gao J. et al. Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison. Chron. Respir. Dis. 2018; 12: 1479972318790269. DOI: 10.1177/1479972318790269.
67. Asintam P., Kiranantawat N., Juthong S. Can roxithromycin improve quality of life in bronchiectatic patients? Eur. Respir. J. 2012; 40: P2168.
68. Lourdesamy A., Muthukumaru U. Efficacy of azithromycin in the treatment of bronchiectasis. Respirology. 2014; 19 (8): 1178–1182. DOI: 10.1111/resp.12375.
69. Sadigov A.S., Mammadov G.T. Azythromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease? Am. J. Respir. Crit. Care Med. 2013; 187: A3512.
70. Haworth C.S., Bilton D., Elborn J.S. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir. Med. 2014; 108 (10): 1397–1408. DOI: 10.1016/j.rmed.2014.09.005.
71. Juthong S., Eiamsa-ard S. Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study. Eur. Respir. J. 2011; 38 (Suppl. 55): 4496.
72. Bonaiti G., Pesci A., Marruchella A. et al. Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis. Biomed. Res. Int. 2015; 2015: 197950. DOI: 10.1155/2015/197950.
73. Olivieri D., Ciaccia A., Marangio E. et al. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration. 1991; 58 (3–4): 117–121.
74. Wilkinson M., Sugumar K., Milan S.J. et al. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD001289. DOI: 10.1002/14651858.CD001289.pub2.
75. Crisafulli E., Coletti O., Costi S. et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin. Ther. 2007; 29 (9): 2001–2009.
Review
For citations:
Chikina S.Yu., Avdeev S.N. Current approaches to pharmacological treatment of adult patients with bronchiectasis. PULMONOLOGIYA. 2019;29(1):71-86. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-1-71-86
Views:
1584
Email this article 